Cantel Medical Corp. Launches RAPICIDE® OPA/28 High-Level Disinfectant Fastest disinfection time and twice the reuse life among OPA-based disinfectants
LITTLE FALLS, N.J., March 6, 2013 /PRNewswire/ -- Cantel Medical Corp. (NYSE: CMN), a leading provider of infection prevention and control products, has officially launched RAPICIDE OPA/28, an ortho-phthalaldehyde (OPA) based high-level disinfectant for semi-critical medical devices, to multiple segments of the healthcare market. A 510(k) cleared product by the FDA, RAPICIDE OPA/28 high-level disinfectant offers a reuse period for up to 28 days, twice the reuse life among all OPA-based disinfectants available on the market, and the fastest manual disinfection time at ten minutes at room temperature.
"We are very pleased to offer our latest disinfection product to broad segments of the healthcare market," said Andrew Krakauer, President and CEO, Cantel Medical Corp. "With close attention to healthcare cost control, increased scrutiny over healthcare-associated infections (HAIs), and higher demand for quality of care, we are excited that RAPICIDE OPA/28 high-level disinfectant is capable of lowering overall reprocessing costs among OPA-based disinfectants while delivering excellent product performance that will enhance the patients' and healthcare workers' use experience."
"Our expertise in infection control and prevention has enabled our success in bringing instrument disinfection technology to the next level," added Jorgen Hansen, Executive Vice President and COO, Cantel Medical Corp. "The launch of RAPICIDE OPA/28 high-level disinfectant is a clear milestone that demonstrates our ability to develop infection control solutions to broader healthcare markets."
RAPICIDE OPA/28 is a convenient, ready-to-use high-level disinfectant designed for use in central processing departments, gastrointestinal departments, surgery centers, physician offices, and other areas where high-level disinfection is required. It can disinfect a wide range of endoscopes and other heat sensitive semi-critical medical devices. The product will be produced and sold via Cantel Medical Corp.'s subsidiaries: MEDIVATORS Inc. (www.medivators.com), Crosstex International (www.crosstex.com), and SPSmedical (www.spsmedical.com).
About Cantel Medical Corp.
Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Our products include water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reprocessing systems for endoscopy and renal dialysis, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates and other dialysis supplies, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.
SOURCE Cantel Medical Corp.